講者：Keira Joann Herr
日期：2019-11-17
觀看: 1015
  • 00:00 1.
    Brintellix (vortioxetine )A new generation of antidepressant Emerging mechanism and treatment for depression beyond SSRIs and SNRIs
  • 07:19 2.
    Disclaimer
  • 07:22 3.
    Suggested content
  • 08:08 4.
    Current hypotheses of depression
  • 10:25 5.
    Current Treatment in depression with SSRIs & SNRIsBrain chemicals & depression
  • 11:54 6.
    SSRI and its mode of action
  • 12:29 7.
    Limitations of SSRI & SNRI Treatment
  • 14:27 8.
    Limitations of current antidepressant treatment
  • 15:32 9.
    Mode of actions of an antidepressant beyond monoamine hypothesisVortioxetine is NOT an SSRI
  • 16:36 10.
    Multimodal: Several targets and impact on several neurotransmitter systems
  • 17:01 11.
    Comparative efficacy and acceptability of 21 antidepressants – head-to-head studies
  • 18:28 12.
    Clinical benefits of a multimodal antidepressantComparative efficacy and acceptability of 21 antidepressants – head-to-head studies
  • 18:43 13.
    Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
  • 19:26 14.
    Cognition in depression: a neglected critical target
  • 19:56 15.
    Vortioxetine regulated glutamate pathwayPotential reason to improve cognitive symptoms
  • 20:33 16.
    Clinical meaningfulness: benchmarking DSST effect size in MDD
  • 21:08 17.
    Meta-analysis assessing effect of antidepressants on cognitive function in MDD
  • 21:55 18.
    Improvement of Vortioxetine in mood and cognition translate to improvement in everyday functioning in patients with MDD1
  • 22:42 19.
    Efficacy of Vortioxetine is replicated data in real world study
  • 24:51 20.
    Vortioxetine improved patient-rated symptoms from baseline to week 52
  • 25:26 21.
    DSST Improvements in Vortioxetine Treated Patients Relative to “Normative” Means in AtWoRC study
  • 26:00 22.
    Vortioxetine-treated patients with missed work days in last 3 months at Baseline and Week 52
  • 26:34 23.
    Vortioxetine also regulated dopamine pathwayPotential reason to avoid emotional blunting & improve adhedonia
  • 26:48 24.
    What is anhedonia?
  • 28:08 25.
    EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
  • 28:17 26.
    What is anhedonia?
  • 28:27 27.
    EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
  • 29:06 28.
    Vortioxetine significantly improved anhedonia: Improvements in SHAPS and MADRS anhedonia score
  • 29:29 29.
    What is anhedonia?
  • 29:51 30.
    Vortioxetine is well-tolerated
  • 30:38 31.
    Clinical experiences with Vortioxetine – case 01
  • 30:40 32.
    Vortioxetine is well-tolerated
  • 31:04 33.
    Clinical experiences with Vortioxetine – case 01
  • 33:56 34.
    Clinical experiences with Vortioxetine – case 02
  • 37:48 35.
    Slide 31
  • 44:59 36.
    Clinical experiences with Vortioxetine – case 02
  • 45:00 37.
    Clinical experiences with Vortioxetine – case 01
  • 45:00 38.
    Vortioxetine is well-tolerated
  • 45:01 39.
    What is anhedonia?
  • 45:03 40.
    Vortioxetine significantly improved anhedonia: Improvements in SHAPS and MADRS anhedonia score
  • 45:03 41.
    EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
  • 45:04 42.
    What is anhedonia?
  • 45:04 43.
    Vortioxetine also regulated dopamine pathwayPotential reason to avoid emotional blunting & improve adhedonia
  • 45:05 44.
    Vortioxetine-treated patients with missed work days in last 3 months at Baseline and Week 52
  • 45:07 45.
    DSST Improvements in Vortioxetine Treated Patients Relative to “Normative” Means in AtWoRC study
  • 45:08 46.
    Vortioxetine improved patient-rated symptoms from baseline to week 52
  • 45:11 47.
    Efficacy of Vortioxetine is replicated data in real world study
  • 45:11 48.
    Improvement of Vortioxetine in mood and cognition translate to improvement in everyday functioning in patients with MDD1
  • 45:12 49.
    Meta-analysis assessing effect of antidepressants on cognitive function in MDD
  • 45:13 50.
    Clinical meaningfulness: benchmarking DSST effect size in MDD
  • 45:13 51.
    Vortioxetine regulated glutamate pathwayPotential reason to improve cognitive symptoms
  • 45:13 52.
    Cognition in depression: a neglected critical target
  • 45:14 53.
    Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
  • 45:15 54.
    Clinical benefits of a multimodal antidepressantComparative efficacy and acceptability of 21 antidepressants – head-to-head studies
  • 45:17 55.
    Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
  • 索引
  • 筆記
  • 討論
  • 全螢幕
Dr William Lo Tak Lam_Vortixetine_Taiwan_For discussion_1117
長度: 1:00:22, 瀏覽: 1016, 最近修訂: 2019-11-17
    上一篇 下一篇
    • 00:00 1.
      Brintellix (vortioxetine )A new generation of antidepressant Emerging mechanism and treatment for depression beyond SSRIs and SNRIs
    • 07:19 2.
      Disclaimer
    • 07:22 3.
      Suggested content
    • 08:08 4.
      Current hypotheses of depression
    • 10:25 5.
      Current Treatment in depression with SSRIs & SNRIsBrain chemicals & depression
    • 11:54 6.
      SSRI and its mode of action
    • 12:29 7.
      Limitations of SSRI & SNRI Treatment
    • 14:27 8.
      Limitations of current antidepressant treatment
    • 15:32 9.
      Mode of actions of an antidepressant beyond monoamine hypothesisVortioxetine is NOT an SSRI
    • 16:36 10.
      Multimodal: Several targets and impact on several neurotransmitter systems
    • 17:01 11.
      Comparative efficacy and acceptability of 21 antidepressants – head-to-head studies
    • 18:28 12.
      Clinical benefits of a multimodal antidepressantComparative efficacy and acceptability of 21 antidepressants – head-to-head studies
    • 18:43 13.
      Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
    • 19:26 14.
      Cognition in depression: a neglected critical target
    • 19:56 15.
      Vortioxetine regulated glutamate pathwayPotential reason to improve cognitive symptoms
    • 20:33 16.
      Clinical meaningfulness: benchmarking DSST effect size in MDD
    • 21:08 17.
      Meta-analysis assessing effect of antidepressants on cognitive function in MDD
    • 21:55 18.
      Improvement of Vortioxetine in mood and cognition translate to improvement in everyday functioning in patients with MDD1
    • 22:42 19.
      Efficacy of Vortioxetine is replicated data in real world study
    • 24:51 20.
      Vortioxetine improved patient-rated symptoms from baseline to week 52
    • 25:26 21.
      DSST Improvements in Vortioxetine Treated Patients Relative to “Normative” Means in AtWoRC study
    • 26:00 22.
      Vortioxetine-treated patients with missed work days in last 3 months at Baseline and Week 52
    • 26:34 23.
      Vortioxetine also regulated dopamine pathwayPotential reason to avoid emotional blunting & improve adhedonia
    • 26:48 24.
      What is anhedonia?
    • 28:08 25.
      EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
    • 28:17 26.
      What is anhedonia?
    • 28:27 27.
      EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
    • 29:06 28.
      Vortioxetine significantly improved anhedonia: Improvements in SHAPS and MADRS anhedonia score
    • 29:29 29.
      What is anhedonia?
    • 29:51 30.
      Vortioxetine is well-tolerated
    • 30:38 31.
      Clinical experiences with Vortioxetine – case 01
    • 30:40 32.
      Vortioxetine is well-tolerated
    • 31:04 33.
      Clinical experiences with Vortioxetine – case 01
    • 33:56 34.
      Clinical experiences with Vortioxetine – case 02
    • 37:48 35.
      Slide 31
    • 44:59 36.
      Clinical experiences with Vortioxetine – case 02
    • 45:00 37.
      Clinical experiences with Vortioxetine – case 01
    • 45:00 38.
      Vortioxetine is well-tolerated
    • 45:01 39.
      What is anhedonia?
    • 45:03 40.
      Vortioxetine significantly improved anhedonia: Improvements in SHAPS and MADRS anhedonia score
    • 45:03 41.
      EEfRT: an objective measure of reward and motivationImproved performance in reward motivation with vortioxetine treatment
    • 45:04 42.
      What is anhedonia?
    • 45:04 43.
      Vortioxetine also regulated dopamine pathwayPotential reason to avoid emotional blunting & improve adhedonia
    • 45:05 44.
      Vortioxetine-treated patients with missed work days in last 3 months at Baseline and Week 52
    • 45:07 45.
      DSST Improvements in Vortioxetine Treated Patients Relative to “Normative” Means in AtWoRC study
    • 45:08 46.
      Vortioxetine improved patient-rated symptoms from baseline to week 52
    • 45:11 47.
      Efficacy of Vortioxetine is replicated data in real world study
    • 45:11 48.
      Improvement of Vortioxetine in mood and cognition translate to improvement in everyday functioning in patients with MDD1
    • 45:12 49.
      Meta-analysis assessing effect of antidepressants on cognitive function in MDD
    • 45:13 50.
      Clinical meaningfulness: benchmarking DSST effect size in MDD
    • 45:13 51.
      Vortioxetine regulated glutamate pathwayPotential reason to improve cognitive symptoms
    • 45:13 52.
      Cognition in depression: a neglected critical target
    • 45:14 53.
      Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
    • 45:15 54.
      Clinical benefits of a multimodal antidepressantComparative efficacy and acceptability of 21 antidepressants – head-to-head studies
    • 45:17 55.
      Meta-analysis: Vortioxetine improves all symptoms of MDD as assessed by MADRS
    位置
    1. 知識庫
    2. 保健中心
    資料夾名稱
    保健中心
    發表人
    江堤莊
    單位
    台大醫學院資訊組
    建立
    2019-11-17 17:19:44
    最近修訂
    2019-11-17 18:50:08
    長度
    1:00:22